270 related articles for article (PubMed ID: 28508387)
21. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
Fujita Y; Shinkuma S; Nomura T; Shimizu H
Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
[No Abstract] [Full Text] [Related]
22. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies.
Antoniou C; Moustou AE; Vergou T; Stratigos A; Kalambokas A; Katsambas AD
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):356-7. PubMed ID: 19686257
[No Abstract] [Full Text] [Related]
23. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
[No Abstract] [Full Text] [Related]
24. Efficacy of ustekinumab in palmoplantar pustulosis.
Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Uthurriague C; Paul C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e204-e206. PubMed ID: 29194805
[No Abstract] [Full Text] [Related]
25. High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab.
Talamonti M; D'Adamio S; Galluccio T; Andreani M; Pastorino R; Egan CG; Bianchi L; Galluzzo M
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e364-e367. PubMed ID: 31066090
[No Abstract] [Full Text] [Related]
26. Successful treatment of ustekinumab in a psoriasis patient with human T-cell leukemia/lymphotropic virus type 1 infection.
Kazama M; Umezawa Y; Itoh M; Nobeyama Y; Ito T; Kikuchi S; Yanaba K; Asahina A; Nakagawa H; Ogasawara Y
J Dermatol; 2017 Nov; 44(11):1334-1335. PubMed ID: 27864824
[No Abstract] [Full Text] [Related]
27. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
Bertrand V; El Haite A; Carré D
Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
[TBL] [Abstract][Full Text] [Related]
28. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
[No Abstract] [Full Text] [Related]
29. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
30. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
Dickson L; Menter A
J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
[TBL] [Abstract][Full Text] [Related]
31. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
[TBL] [Abstract][Full Text] [Related]
32. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
[TBL] [Abstract][Full Text] [Related]
33. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
[No Abstract] [Full Text] [Related]
34. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
Jack C; Mashiko S; Arbour N; Bissonnette R; Sarfati M
Br J Dermatol; 2017 Jul; 177(1):267-270. PubMed ID: 27599204
[No Abstract] [Full Text] [Related]
35. Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis.
Morgado-Carrasco D; Riera-Monroig J; Fustà-Novell X; Alsina Gibert M
Actas Dermosifiliogr (Engl Ed); 2018; 109(6):565-567. PubMed ID: 29169562
[No Abstract] [Full Text] [Related]
36. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
37. Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.
Onderdijk AJ; Ijpma AS; Menting SP; Baerveldt EM; Prens EP
Br J Dermatol; 2015 Dec; 173(6):1536-9. PubMed ID: 26134667
[No Abstract] [Full Text] [Related]
38. Excellent response to ustekinumab in a 9-year-old girl with severe psoriasis.
González-Barreto RM; Rochet NM; Nevares-Pomales OW; Colón-Fontanez F
Pediatr Dermatol; 2018 Jan; 35(1):e76-e78. PubMed ID: 29205479
[TBL] [Abstract][Full Text] [Related]
39. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
40. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
